Degrading proteins, block by block

Our KRAS review last week included a lot of different inhibitor compounds (well over 30 of them), illustrating just how complex this niche is rapidly becoming, with only a brief mention of targeted protein degrader (TPD) compounds since these are much further behind their small molecule inhibitor counterparts.

Since then there’s been some more big picture talks or three about the TPD space, which are well worth discussing, as well as a flurry of relevant questions from BSB readers to be addressed.

Here we discuss the KRAS niche in the context of protein degraders and look at the promise and some of the inherent challenges faced…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by